These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36039651)

  • 1. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
    Tsubokura Y; Yoshimura H; Satake A; Nasa Y; Tsuji R; Ito T; Nomura S
    Immun Inflamm Dis; 2022 Sep; 10(9):e688. PubMed ID: 36039651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
    Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
    Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
    Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
    Front Immunol; 2021; 12():757836. PubMed ID: 34712243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minnelide suppresses GVHD and enhances survival while maintaining GVT responses.
    Copsel SN; Garrido VT; Barreras H; Bader CS; Pfeiffer B; Mateo-Victoriano B; Wolf D; Gallardo M; Paczesny S; Komanduri KV; Benjamin CL; Villarino AV; Saluja AK; Levy RB
    JCI Insight; 2024 Apr; 9(9):. PubMed ID: 38602775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
    Huang W; Chao NJ
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):211-219. PubMed ID: 28636890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
    MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
    Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
    Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
    Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
    Alsina M; Becker PS; Zhong X; Adams A; Hari P; Rowley S; Stadtmauer EA; Vesole DH; Logan B; Weisdorf D; Qazilbash M; Popplewell LL; McClune B; Bensinger W; Riches M; Giralt SA; Pasquini MC;
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1183-9. PubMed ID: 24769014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
    Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
    Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
    Craddock C; Slade D; De Santo C; Wheat R; Ferguson P; Hodgkinson A; Brock K; Cavenagh J; Ingram W; Dennis M; Malladi R; Siddique S; Mussai F; Yap C
    J Clin Oncol; 2019 Mar; 37(7):580-588. PubMed ID: 30653424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
    Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft conditioning with fluticasone propionate reduces graft-versus-host disease upon allogeneic hematopoietic cell transplantation in mice.
    Varady ES; Ayala LA; Nguyen PU; Scarfone VM; Karimzadeh A; Zhou C; Chen X; Greilach SA; Walsh CM; Inlay MA
    EMBO Mol Med; 2023 Sep; 15(9):e17748. PubMed ID: 37538042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression.
    Albring JC; Sandau MM; Rapaport AS; Edelson BT; Satpathy A; Mashayekhi M; Lathrop SK; Hsieh CS; Stelljes M; Colonna M; Murphy TL; Murphy KM
    J Exp Med; 2010 Nov; 207(12):2551-9. PubMed ID: 21078889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.